AEterna Zentaris Inc. (AEZS)

[~ Blue ~]

Zoptarelin doxorubicin has the potential to be the first FDA approved medication for endometrial cancer. October is just a few weeks away.

"We believe that zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer. This could result in its rapid adoption as a novel core therapy for treatment and management of advanced, recurrent endometrial cancer. Our hope is that the compound will improve and extend the quality of the lives of patients with this devastating disease."